| RRC ID |
67829
|
| 著者 |
Noguchi T, Hidaka K, Kobayashi S, Matsumoto K, Yoshioka M, Hu X, Maloney DJ, Yang SM, Kato S.
|
| タイトル |
A quinazoline-based bromodomain inhibitor, CN210, ameliorates indomethacin-induced ileitis in mice by inhibiting inflammatory cytokine expression.
|
| ジャーナル |
Drug Dev Res
|
| Abstract |
Inhibitors of bromodomain and extra-terminal motif (BET) proteins are emerging epigenetic therapeutics that suppress gene expressions that drive cancer and inflammation. The present study examined anti-inflammatory effects of a quinazoline-based BET inhibitor, CN210, in a murine ileitis model. CN210 was given orally 30 min before and 24 h after a subcutaneous administration of indomethacin. Macroscopic and histological evidences of ileitis, mucosal myeloperoxidase (MPO) activity and cytokine expressions were evaluated 48 h after the indomethacin administration. To further characterize the anti-inflammatory pathways modulated by CN210, its effects on RAW264 cells treated with lipopolysaccharide (LPS) were investigated. Competitive ligand binding and docking studies of CN210 to CREB-binding protein (CBP) and p300 were also performed. Oral administration of CN210 significantly reduced the severity of ileitis, normalized both proinflammatory MPO activity and concomitant cytokine expressions induced by indomethacin administration. Furthermore, CN210 attenuated the expression of cytokines and reversed the activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinases (MAPK) induced by LPS. Competitive ligand binding assays showed that CN210 bound to the bromodomains of two paralogous histone acetyltransferases, CBP and p300, in addition to the bromodomains of BET proteins. Docking studies of CN210 to the bromodomains of CBP and p300 showed a similarity to the binding mode of SGC-CBP30, a specific CBP/p300 inhibitor. CN210 ameliorates indomethacin-induced ileitis by inhibiting the expression of inflammatory cytokines through the attenuation of NF-κB and MAPK pathways. CN210 thus represents a new mode of therapy for non-steroidal anti-inflammatory drug-induced ileitis and inflammatory bowel disease.
|
| 巻・号 |
82(8)
|
| ページ |
1235-1246
|
| 公開日 |
2021-12-1
|
| DOI |
10.1002/ddr.21838
|
| PMID |
34075610
|
| PMC |
PMC8637501
|
| MeSH |
Animals
Anti-Inflammatory Agents / pharmacology*
Cytokines / antagonists & inhibitors*
Cytokines / biosynthesis
E1A-Associated p300 Protein / metabolism
Ileitis / chemically induced
Ileitis / drug therapy*
Indomethacin / adverse effects*
Male
Membrane Proteins / metabolism
Mice
Mice, Inbred C57BL
NF-kappa B / physiology
Peroxidase / metabolism
Phosphoproteins / metabolism
Proteins / antagonists & inhibitors*
Quinazolines / pharmacology
RAW 264.7 Cells
|
| リソース情報 |
| ヒト・動物細胞 |
RAW 264(RCB0535) |
